NEW YORK (GenomeWeb) – Roche today announced that the Global Fund has selected the company as a supplier of early infant and viral load HIV diagnostics.
Roche will supply two tests, both of which use a dual-target design to amplify and detect two regions of the HIV-1 genome not subject to selective drug pressure, the firm said in a statement.
The cobas AmpliPrep/cobas TaqMan HIV-1 Test v2.0 detects group M and O strains of HIV-1 and has a broad dynamic range for viral load monitoring. The test runs on the firm's fully automated real-time PCR platform.
The cobas AmpliPrep/cobas TaqMan HIV-1 Qualitative Test v2.0 detects total nucleic acid in plasma or dried blood spots and is meant to diagnose active infection in adults and infants born to infected mothers.
The Global Fund is a partnership between governments, the private sector, and other stakeholders that invests nearly $4 billion per year in programs to end epidemics of AIDS, tuberculosis, and malaria.